SCYNEXIS

About SCYNEXIS

Scynexis is a leading anti-infective company committed to protecting the world against dangerous and difficult-to-treat fungal pathogens. They focus on innovative solutions to combat infectious diseases, particularly life-threatening fungal infections, with a mission to bring meaningful scientific breakthroughs that change lives.

Products & Services

SCY-247:A second-generation fungerp candidate for treating invasive fungal infections, currently in clinical trials.

Ibrexafungerp:An anti-fungal agent under development for various fungal infections.

Specialties

Anti-fungal agents Infectious disease treatment Life-threatening fungal infections Anti-microbial resistance

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Milestone Payment T: - FT: Milestone Payment	A: 10000000 MR: - FA: 10 million FAN: 10000000	D: 2024-07-23 FD: 2024-07-23	1 investors

Milestone Payment Latest

2024-07-23

$10.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Angulo

President and Chief Executive Officer

S

Scott Sukenick

Chief Legal Officer

I

Ivor Macleod

Chief Financial Officer

D

Daniella Gigante

Vice President, Human Resources and Information Technology

R

Rossana Ferrara-Pontoriero

Vice President, Business Development and Alliance Management

G

Guy Macdonald

Chairman of the Board

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

SCYNEXIS Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised